Since the loss or mutation of p53 function is associated with increased cancer susceptibility, reactivating WT p53 in those tumours where its function has been suppressed has been a target of several small molecule inhibitors currently being studied or being evaluated in the clinic (Figure 1). The gene discussed is TP53; the disease is neoplasm.